Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06UPS
|
|||
| Former ID |
DIB014510
|
|||
| Drug Name |
Rozrolimupab
|
|||
| Synonyms |
SYM-001; Symphoglobulin-D; Recombinant human polyclonal antibodies (rhesus D), Symphogen/Biovitrum; Recombinant polyclonal antibodies (idiopathic thrombocytopenic purpura), Symphogen/Biovitrum; Symphobodies (hemolytic disease of the newborn), Symphogen/Biovitrum; Anti-RhD (trombocytopeni, anti-D-profylax), Symphogen/Biovitrum
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Discontinued in Phase 2 | [1] | |
| Company |
Symphogen A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Blood group Rh(D) polypeptide (RHD) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025976) | |||
| REF 2 | Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec;12(6):734-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.